J Clin Oncol 2020 May 10
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Related Questions
Does the 2020 approval of Nivolumab and Ipilimumab for mNSCLC with PDL1 >1% impact your decision?
New answer by Medical Oncologist at Karmanos Cancer Institute (February 5, 2022)
For chemo eligible patients, I still favor chemo-IO combination (KEYNOTE-189 regimen). This trial has the best data so far for PD-L1 (22c3) TPS: 1-49% (ORR ~ 49% Md DOR 12...
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (June 27, 2022)
The FDA approved Sotarasib based on results from a subset of patients in CodeBreaK100, exclusively for patients with the KRAS G12C mutation showing favorable efficacy and tole...